,Gene,Gene synonym,Ensembl,Gene description,Chromosome,Position,Protein class,Evidence,Antibody,Reliability (IH),Reliability (Mouse Brain),Reliability (IF),Subcellular location,Prognostic p-value,RNA cancer category,RNA tissue category,RNA TS,RNA TS TPM,TPM max in non-specific,RNA cell line category,RNA CS,RNA CS TPM
0,DEFB119,"DEFB-19, DEFB-20, DEFB120",ENSG00000180483,Defensin beta 119,20,31377164-31390603,Predicted secreted proteins,Evidence at protein level,HPA043059,Supported,,,,,Tissue enriched,Group enriched,3499,epididymis: 2335.6;testis: 472.8,duodenum: 0.4,Not detected,,
1,DEFB123,DEFB-23,ENSG00000180424,Defensin beta 123,20,31440519-31450257,Predicted secreted proteins,Evidence at protein level,,,,,,,Tissue enriched,Group enriched,438,epididymis: 108.1;testis: 178.0,small intestine: 0.3,Not detected,,
2,MAGEB3,CT3.5,ENSG00000198798,MAGE family member B3,X,30230436-30237492,Predicted intracellular proteins,Evidence at protein level,HPA072203,Approved,,,,,Not detected,Group enriched,156,epididymis: 21.5;testis: 9.5,all non-specific tissues: 0.0,Cell line enriched,10.0,U-266/70: 1.6
3,EPPIN,"CT71, dJ461P17.2, EPPIN1, EPPIN2, EPPIN3, SPINLW1, WAP7, WFDC7",ENSG00000101448,Epididymal peptidase inhibitor,20,45540626-45547752,"Predicted intracellular proteins, Predicted secreted proteins",Evidence at protein level,,,,,,,Not detected,Group enriched,117,epididymis: 414.2;testis: 128.4,fallopian tube: 2.3,Cell line enhanced,,U-87 MG: 2.6
4,MAGEB4,"CT3.6, MGC33144",ENSG00000120289,MAGE family member B4,X,30242052-30244193,Predicted intracellular proteins,Evidence at protein level,HPA030456,Enhanced,,,,,Not detected,Group enriched,117,epididymis: 34.1;testis: 17.0,breast: 0.2,Not detected,,
5,SLC22A11,OAT4,ENSG00000168065,Solute carrier family 22 member 11,11,64555626-64572875,"FDA approved drug targets, Plasma proteins, Predicted membrane proteins, Transporters",Evidence at protein level,HPA026076,Approved,,,,Renal cancer:3.68e-5 (favourable),Group enriched,Group enriched,114,epididymis: 10.0;kidney: 26.0;placenta: 44.8,seminal vesicle: 0.2,Cell line enhanced,,BEWO: 1.2
6,CAMP,"CAP18, FALL-39, FALL39, LL37",ENSG00000164047,Cathelicidin antimicrobial peptide,3,48223347-48225491,Predicted secreted proteins,Evidence at protein level,"CAB015949, CAB016522, HPA029874",Enhanced,,,,Cervical cancer:5.73e-4 (favourable),Tissue enhanced,Group enriched,101,bone marrow: 1341.0;epididymis: 330.5,lymph node: 8.2,Group enriched,12.0,Daudi: 18.4;hTCEpi: 12.5;U-698: 50.9
7,EPPIN-WFDC6,SPINLW1-WFDC6,ENSG00000249139,EPPIN-WFDC6 readthrough,20,45536986-45547426,Predicted secreted proteins,Evidence at protein level,,,,,,,Not detected,Group enriched,78,epididymis: 41.7;testis: 58.2,fallopian tube: 0.6,Not detected,,
8,POU3F3,"BRN1, OTF8",ENSG00000198914,POU class 3 homeobox 3,2,104855511-104858574,"Predicted intracellular proteins, Transcription factors",Evidence at protein level,"HPA052792, HPA056039, HPA067151",Approved,,Enhanced,Nucleus,Endometrial cancer:4.26e-5 (unfavourable),Group enriched,Group enriched,45,cerebral cortex: 43.9;epididymis: 46.3;kidney: 36.6;seminal vesicle: 23.2,skin: 0.8,Group enriched,5.0,AF22: 58.4;AN3-CA: 52.7;HEK93: 20.3;RPTEC TERT1: 50.7;SH-SY5Y: 19.7
9,DNAJC5G,"CSP-gamma, FLJ40417",ENSG00000163793,DnaJ heat shock protein family (Hsp40) member C5 gamma,2,27275421-27281499,Predicted membrane proteins,Evidence at transcript level,HPA041445,Approved,,,,,Not detected,Group enriched,41,epididymis: 65.0;testis: 42.7,cerebral cortex: 1.3,Cell line enhanced,,HAP1: 1.0
10,U82695.5,,ENSG00000214897,,X,153395640-153401420,Predicted intracellular proteins,Evidence at transcript level,,,,,,,Mixed,Group enriched,35,epididymis: 5.8;ovary: 4.7;testis: 10.9,fallopian tube: 0.2,Not detected,,
11,KRT71,"K6IRS1, KRT6IRS, KRT6IRS1",ENSG00000139648,Keratin 71,12,52543909-52553147,"Disease related genes, Plasma proteins, Predicted intracellular proteins",Evidence at protein level,HPA049404,Supported,,,,,Tissue enhanced,Group enriched,34,breast: 1.4;epididymis: 5.3,all non-specific tissues: 0.0,Cell line enriched,11.0,CACO-2: 5.1
12,RP11-14J7.7,,ENSG00000259060,Probable ribonuclease 11 precursor ,14,20582892-20609795,Predicted secreted proteins,Evidence at transcript level,,,,,,,Not detected,Group enriched,34,epididymis: 5.4;testis: 1.2,all non-specific tissues: 0.0,Not detected,,
13,SPINT3,HKIB9,ENSG00000101446,"Serine peptidase inhibitor, Kunitz type 3",20,45512461-45515624,Predicted secreted proteins,Evidence at protein level,HPA026852,Enhanced,,,,,Not detected,Group enriched,32,epididymis: 5.8;seminal vesicle: 15.4,skin: 0.3,Not detected,,
14,AC133551.1,,ENSG00000274175,,Unmapped,17234-19833,Predicted intracellular proteins,Evidence at transcript level,,,,,,,,Group enriched,28,epididymis: 7.4;testis: 4.1,placenta: 0.2,Not detected,,
15,CDY2A,CDY2,ENSG00000182415,Chromodomain Y-linked 2A,Y,18025787-18028597,"Enzymes, Predicted intracellular proteins",Evidence at protein level,,,,,,,Not detected,Group enriched,24,epididymis: 1.3;testis: 3.5,all non-specific tissues: 0.0,Not detected,,
16,NXF2,"CT39, TAPL-2",ENSG00000269405,Nuclear RNA export factor 2,X,102247161-102326719,Predicted intracellular proteins,Evidence at protein level,HPA002079,Uncertain,,,,,Not detected,Group enriched,21,epididymis: 18.6;testis: 23.3,fallopian tube: 0.9,Cell line enriched,38.0,U-266/84: 24.8
17,ROS1,"c-ros-1, MCF3, ROS",ENSG00000047936,"ROS proto-oncogene 1, receptor tyrosine kinase",6,117288300-117425855,"Cancer-related genes, Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins, Predicted membrane proteins",Evidence at protein level,"HPA049098, HPA072424",Uncertain,,Approved,Vesicles,,Tissue enriched,Group enriched,18,epididymis: 70.9;lung: 47.2,seminal vesicle: 3.2,Cell line enhanced,,HSkMC: 7.5;hTCEpi: 15.7;LHCN-M2: 12.7
18,LEMD1,"CT50, LEMP-1",ENSG00000186007,LEM domain containing 1,1,205381378-205457091,"Predicted intracellular proteins, Predicted membrane proteins",Evidence at transcript level,HPA045425,,,Approved,Nucleoli<br>Cytosol,"Ovarian cancer:1.26e-4 (favourable), Pancreatic cancer:1.70e-4 (unfavourable)",Tissue enhanced,Group enriched,16,epididymis: 18.1;testis: 71.4,fallopian tube: 2.7,Group enriched,6.0,CAPAN-2: 34.9;NTERA-2: 7.0
19,WFDC6,"C20orf171, dJ461P17.11, WAP6",ENSG00000243543,WAP four-disulfide core domain 6,20,45534196-45539495,Predicted secreted proteins,Evidence at transcript level,,,,,,,Tissue enhanced,Group enriched,16,epididymis: 323.7;testis: 83.8,fallopian tube: 12.5,Cell line enriched,7.0,U-87 MG: 2.6
20,MAGEA11,"CT1.11, MAGE-11, MAGE11, MAGEA-11, MGC10511",ENSG00000185247,MAGE family member A11,X,149688228-149717266,Predicted intracellular proteins,Evidence at protein level,HPA052687,,,Supported,Nucleoplasm<br>Nuclear bodies<br>Cytosol,,Mixed,Group enriched,15,epididymis: 25.8;testis: 6.9,placenta: 1.0,Cell line enhanced,,PC-3: 5.2;U-2 OS: 25.0;U-2197: 3.2
21,REG3G,"LPPM429, PAP1B, UNQ429",ENSG00000143954,Regenerating family member 3 gamma,2,79025686-79028505,Predicted secreted proteins,Evidence at protein level,"HPA047894, HPA048334, HPA060705",Uncertain,,Approved,Cytosol,,Tissue enriched,Group enriched,15,epididymis: 201.5;testis: 107.2,pancreas: 10.0,Not detected,,
22,TP53TG3F,,ENSG00000278848,TP53 target 3 family member F,16,33459045-33462249,Predicted intracellular proteins,Evidence at transcript level,,,,,,,Not detected,Group enriched,14,epididymis: 7.4;testis: 4.2,placenta: 0.4,Cell line enhanced,,HEL: 1.0
23,PNMA3,"MA3, MA5, MGC132756, MGC132758",ENSG00000183837,Paraneoplastic Ma antigen 3,X,153056409-153060467,Predicted intracellular proteins,Evidence at transcript level,HPA047920,Approved,,,,Endometrial cancer:4.14e-5 (unfavourable),Mixed,Group enriched,13,cerebral cortex: 15.4;epididymis: 45.4;testis: 12.3,fallopian tube: 1.8,Cell line enhanced,,NTERA-2: 3.2;SCLC-21H: 1.2
24,CTNNA2,"CAP-R, CT114",ENSG00000066032,Catenin alpha 2,2,79185231-80648861,"Plasma proteins, Predicted intracellular proteins",Evidence at protein level,CAB037175,Enhanced,,,,,Group enriched,Group enriched,12,cerebral cortex: 111.6;epididymis: 81.5;testis: 32.2,adrenal gland: 6.3,Cell line enhanced,,AF22: 7.0;Karpas-707: 5.9;NTERA-2: 6.7;SCLC-21H: 4.5;SH-SY5Y: 11.4
25,SLC30A3,ZNT3,ENSG00000115194,Solute carrier family 30 member 3,2,27253684-27275817,"Predicted membrane proteins, Transporters",Evidence at protein level,"HPA060505, HPA067637, CAB079044",Enhanced,Approved,Approved,Nucleus<br>Nucleoli<br>Vesicles<br>Cytosol,,Mixed,Group enriched,12,cerebral cortex: 36.6;epididymis: 55.4;testis: 43.5,heart muscle: 3.6,Cell line enhanced,,HAP1: 10.6;Hep G2: 9.5;REH: 20.7;RH-30: 11.0
26,DEFB125,DEFB-25,ENSG00000178591,Defensin beta 125,20,87250-97094,Predicted secreted proteins,Evidence at transcript level,HPA043095,Uncertain,,,,,Not detected,Group enriched,11,epididymis: 1.3;seminal vesicle: 1.5,testis: 0.1,Not detected,,
27,MCF2,"ARHGEF21, DBL",ENSG00000101977,MCF.2 cell line derived transforming sequence,X,139581770-139708227,"Plasma proteins, Predicted intracellular proteins",Evidence at protein level,,,,,,,Not detected,Group enriched,11,adrenal gland: 38.3;cerebral cortex: 8.7;epididymis: 15.0;ovary: 12.9;seminal vesicle: 24.0;testis: 34.6,prostate: 2.0,Cell line enriched,12.0,U-251 MG: 30.6
28,SRD5A2,,ENSG00000277893,Steroid 5 alpha-reductase 2,2,31522480-31581067,"Cancer-related genes, Disease related genes, Enzymes, FDA approved drug targets, Predicted membrane proteins",Evidence at protein level,,,,,,,Group enriched,Group enriched,11,epididymis: 27.9;fallopian tube: 31.6;liver: 30.6;prostate: 26.6;seminal vesicle: 24.5,testis: 2.5,Cell line enhanced,,RT4: 1.2
29,ADIG,"MGC39724, RP5-1100H13.2, SMAF1",ENSG00000182035,Adipogenin,20,38581195-38588463,"Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins",Evidence at transcript level,HPA041124,Uncertain,,,,,Tissue enhanced,Group enriched,10,epididymis: 5.1;testis: 16.1;thyroid gland: 3.4,seminal vesicle: 0.8,Not detected,,
30,DCSTAMP,"DC-STAMP, FIND, TM7SF4",ENSG00000164935,Dendrocyte expressed seven transmembrane protein,8,104339087-104356689,"Predicted membrane proteins, Transporters",Evidence at protein level,,,,,,,Tissue enriched,Group enriched,10,epididymis: 2.4;lung: 5.6,"cerebral cortex,cervix, uterine,lymph node,urinary bladder: 0.3",Not detected,,
31,CCNB3,,ENSG00000147082,Cyclin B3,X,50202713-50351910,Predicted intracellular proteins,Evidence at protein level,HPA000496,Enhanced,,Supported,Nuclear speckles,,Not detected,Group enriched,9,epididymis: 5.8;testis: 7.9,cerebral cortex: 0.7,Cell line enhanced,,CAPAN-2: 1.5
32,COL2A1,"AOM, SEDC, STL1",ENSG00000139219,Collagen type II alpha 1 chain,12,47972965-48004486,"Cancer-related genes, Disease related genes, Predicted secreted proteins",Evidence at protein level,"CAB002214, HPA055753",Supported,,Approved,Nucleoplasm,,Mixed,Group enriched,9,epididymis: 23.0;stomach: 6.2,prostate: 1.6,Group enriched,23.0,AF22: 154.1;HAP1: 101.9;HEK93: 33.7
33,LOXHD1,"DFNB77, FLJ32670, LH2D1",ENSG00000167210,Lipoxygenase homology domains 1,18,46476972-46657033,"Disease related genes, Predicted intracellular proteins",Evidence at protein level,,,,,,,Tissue enhanced,Group enriched,9,epididymis: 8.3;testis: 41.3,fallopian tube: 2.6,Not detected,,
34,ADCY8,"AC8, ADCY3, HBAC1",ENSG00000155897,Adenylate cyclase 8,8,130780301-131042426,"Enzymes, Predicted intracellular proteins, Predicted membrane proteins",Evidence at protein level,"CAB018652, HPA024291",Supported,,,,,Group enriched,Group enriched,8,cerebral cortex: 12.9;epididymis: 27.8;fallopian tube: 6.2,seminal vesicle: 2.0,Group enriched,7.0,U-138 MG: 17.5;U-87 MG: 33.7
35,C5orf67,,ENSG00000225940,Chromosome 5 open reading frame 67,5,56511567-56606232,Predicted intracellular proteins,Evidence at transcript level,,,,,,,Tissue enhanced,Group enriched,8,epididymis: 19.8;kidney: 9.4,thyroid gland: 1.9,Group enriched,7.0,CACO-2: 1.7;EFO-21: 5.3;U-266/70: 4.8
36,DACH2,,ENSG00000126733,Dachshund family transcription factor 2,X,86148458-86832604,Predicted intracellular proteins,Evidence at transcript level,HPA000258,Approved,,,,,Not detected,Group enriched,8,cerebral cortex: 11.9;epididymis: 4.4;fallopian tube: 5.0,kidney: 0.8,Cell line enriched,8.0,HAP1: 6.1
37,DRICH1,C22orf43,ENSG00000189269,Aspartate rich 1,22,23608452-23632321,Predicted intracellular proteins,Evidence at protein level,HPA020446,,,Approved,Nucleus<br>Nucleoli,,Mixed,Group enriched,8,epididymis: 20.8;parathyroid gland: 23.9;testis: 81.2,endometrium: 5.4,Cell line enhanced,,CACO-2: 9.2
38,LRGUK,"CFAP246, FLJ32786",ENSG00000155530,Leucine rich repeats and guanylate kinase domain containing,7,134127299-134264591,Predicted intracellular proteins,Evidence at protein level,"HPA029505, HPA029506",Uncertain,,,,,Mixed,Group enriched,8,epididymis: 1.7;fallopian tube: 5.4;testis: 8.4,"lung,thyroid gland: 0.6",Cell line enhanced,,NTERA-2: 1.4;SH-SY5Y: 1.3;SK-MEL-30: 1.4
39,PRAME,"CT130, MAPE",ENSG00000185686,Preferentially expressed antigen in melanoma,22,22547701-22559361,"Plasma proteins, Predicted intracellular proteins",Evidence at protein level,HPA045153,Enhanced,,,,"Renal cancer:7.48e-9 (unfavourable), Head and neck cancer:3.41e-4 (unfavourable)",Group enriched,Group enriched,8,epididymis: 17.1;testis: 80.5,endometrium: 6.3,Cell line enhanced,,HMC-1: 154.1;K-562: 872.4;SH-SY5Y: 199.7;U-2 OS: 171.5
40,PROKR1,"GPR73, GPR73a, PKR1, ZAQ",ENSG00000169618,Prokineticin receptor 1,2,68643589-68658247,"G-protein coupled receptors, Predicted membrane proteins",Evidence at protein level,HPA029396,Uncertain,,,,,Not detected,Group enriched,8,adipose tissue: 1.7;adrenal gland: 1.4;epididymis: 4.3,testis: 0.3,Cell line enhanced,,NTERA-2: 2.0
41,PXDNL,"FLJ25471, PMR1",ENSG00000147485,Peroxidasin like,8,51319578-51809445,"Enzymes, Predicted intracellular proteins, Predicted secreted proteins",Evidence at protein level,HPA007919,,,Approved,Nucleoplasm<br>Cytosol,Breast cancer:3.27e-5 (unfavourable),Mixed,Group enriched,8,epididymis: 11.5;heart muscle: 24.1;testis: 9.0,adipose tissue: 1.8,Group enriched,7.0,AF22: 7.6;Daudi: 4.2;SH-SY5Y: 6.5
42,RP11-397G17.1,,ENSG00000226733,,6,50093616-50181007,Predicted intracellular proteins,Evidence at transcript level,,,,,,,Group enriched,Group enriched,8,epididymis: 136.0;kidney: 50.9,liver: 12.3,Not detected,,
43,SAG,"ARRESTIN, RP47",ENSG00000130561,S-antigen visual arrestin,2,233307816-233347055,"Disease related genes, Predicted intracellular proteins",Evidence at protein level,HPA004946,Supported,,,,,Not detected,Group enriched,8,epididymis: 1.1;testis: 1.9,endometrium: 0.1,Not detected,,
44,SMIM24,"C19orf77, HSPC323",ENSG00000095932,Small integral membrane protein 24,19,3473986-3480542,"Predicted intracellular proteins, Predicted membrane proteins",Evidence at protein level,"HPA045046, HPA056027",Enhanced,,Approved,Nucleoplasm<br>Cytosol,Renal cancer:4.13e-10 (favourable),Tissue enhanced,Group enriched,8,duodenum: 758.8;epididymis: 1928.7;kidney: 835.9;small intestine: 682.3,stomach: 140.0,Group enriched,8.0,CACO-2: 128.5;HEL: 66.3;Hep G2: 79.7;MOLT-4: 90.8;REH: 56.0;U-937: 68.2
45,TDRD12,"ECAT8, FLJ13072",ENSG00000173809,Tudor domain containing 12,19,32719753-32829580,"Enzymes, Predicted intracellular proteins",Evidence at protein level,,,,,,,Tissue enriched,Group enriched,8,epididymis: 10.9;testis: 33.5,ovary: 2.6,Group enriched,34.0,HDLM-2: 23.6;NTERA-2: 93.5
46,ARHGAP40,"C20orf95, dJ1100H13.4",ENSG00000124143,Rho GTPase activating protein 40,20,38601934-38651035,Predicted intracellular proteins,Evidence at protein level,"HPA042636, HPA042840",Uncertain,,Supported,Nucleoplasm<br>Plasma membrane<br>Centrosome<br>Cytosol,Renal cancer:2.89e-4 (unfavourable),Mixed,Group enriched,7,breast: 38.1;epididymis: 43.7;esophagus: 12.6;seminal vesicle: 11.3;skin: 53.8,prostate: 4.4,Cell line enhanced,,BEWO: 8.0;HBEC3-KT: 9.7;RPTEC TERT1: 8.8;SK-BR-3: 9.5;T-47d: 14.4
47,GOLGA7B,"bA451M19.3, bA459F3.4, C10orf132, C10orf133",ENSG00000155265,Golgin A7 family member B,10,97850239-97871580,Predicted intracellular proteins,Evidence at protein level,HPA046878,Uncertain,,,,,Mixed,Group enriched,7,cerebral cortex: 18.3;epididymis: 28.5;skin: 17.4,adrenal gland: 3.1,Cell line enhanced,,A-431: 4.7;HDLM-2: 5.4;SK-MEL-30: 17.6
48,MSH4,,ENSG00000057468,MutS homolog 4,1,75796882-75913238,Predicted intracellular proteins,Evidence at protein level,,,,,,,Not detected,Group enriched,7,epididymis: 2.3;testis: 7.7,spleen: 0.7,Cell line enhanced,,AN3-CA: 1.6
49,PRDM9,"KMT8B, MSBP3, PFM6, ZNF899",ENSG00000164256,PR/SET domain 9,5,23443586-23528597,"Enzymes, Predicted intracellular proteins, Transcription factors",Evidence at protein level,HPA059555,Uncertain,,,,,Not detected,Group enriched,7,epididymis: 1.7;testis: 7.1,bone marrow: 0.6,Cell line enriched,7.0,U-266/70: 5.0
50,TEX30,C13orf27,ENSG00000151287,Testis expressed 30,13,102765990-102773811,Predicted intracellular proteins,Evidence at protein level,HPA053545,Enhanced,,,,"Prostate cancer:2.10e-6 (unfavourable), Cervical cancer:2.09e-5 (favourable)",Expressed in all,Group enriched,7,epididymis: 87.8;testis: 223.6,placenta: 22.3,Cell line enhanced,,NB-4: 184.1
51,ACOXL,FLJ11042,ENSG00000153093,Acyl-CoA oxidase-like,2,110732573-111118222,Predicted intracellular proteins,Evidence at protein level,"HPA035392, HPA035393",,,Supported,Nucleoli<br>Cytosol,Urothelial cancer:6.48e-4 (favourable),Group enriched,Group enriched,6,epididymis: 9.2;lung: 14.5;parathyroid gland: 6.9;prostate: 5.2;testis: 5.2;urinary bladder: 7.6,thyroid gland: 1.3,Cell line enhanced,,A-431: 11.1;RPMI-8226: 15.9;RT4: 23.3;U-266/70: 14.6
52,ARSF,,ENSG00000062096,Arylsulfatase F,X,3041471-3112726,Predicted membrane proteins,Evidence at protein level,HPA000549,,,Uncertain,Cytosol,,Tissue enhanced,Group enriched,6,adrenal gland: 4.0;cerebral cortex: 2.1;epididymis: 2.0;esophagus: 2.3;kidney: 8.0;skin: 6.7,liver: 0.6,Not detected,,
53,ATP6V1E2,"ATP6E1, ATP6EL2, ATP6V1EL2, MGC9341, VMA4",ENSG00000250565,ATPase H+ transporting V1 subunit E2,2,46490750-46542557,Predicted intracellular proteins,Evidence at protein level,HPA052784,Uncertain,,,,,Expressed in all,Group enriched,6,epididymis: 7.7;testis: 31.6,cerebral cortex: 3.2,Mixed,,
54,C9orf116,"MGC29761, PIERCE1, RbEST47",ENSG00000160345,Chromosome 9 open reading frame 116,9,135495181-135501734,Predicted intracellular proteins,Evidence at protein level,"HPA021439, HPA065287",Approved,,Approved,Nucleoplasm<br>Cytosol,Endometrial cancer:3.53e-5 (favourable),Expressed in all,Group enriched,6,epididymis: 31.1;fallopian tube: 154.4;testis: 63.3,thyroid gland: 13.6,Cell line enhanced,,T-47d: 39.2;U-2197: 39.8
55,CYP4F2,,ENSG00000186115,Cytochrome P450 family 4 subfamily F member 2,19,15878023-15898120,"Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins",Evidence at protein level,"HPA014048, HPA017265, HPA058960",Supported,,,,,Tissue enriched,Group enriched,6,duodenum: 78.2;epididymis: 28.0;kidney: 39.3;liver: 84.6;small intestine: 84.3,prostate: 10.4,Cell line enhanced,,Hep G2: 2.5
56,DCXR,"DCR, KIDCR, SDR20C1",ENSG00000169738,Dicarbonyl and L-xylulose reductase,17,82035136-82037732,"Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted intracellular proteins",Evidence at protein level,"HPA023371, HPA023863",Enhanced,,Uncertain,Nucleoli<br>Microtubules,"Renal cancer:2.13e-4 (favourable), Pancreatic cancer:4.70e-4 (favourable)",Expressed in all,Group enriched,6,epididymis: 297.5;kidney: 217.3;liver: 640.9;prostate: 137.5,adipose tissue: 56.7,Expressed in all,,
57,ECM1,,ENSG00000143369,Extracellular matrix protein 1,1,150508062-150513789,"Disease related genes, Plasma proteins, Predicted secreted proteins",Evidence at protein level,HPA027241,Enhanced,,Approved,Nucleoplasm<br>Cytosol,"Renal cancer:1.51e-9 (unfavourable), Urothelial cancer:1.20e-5 (unfavourable), Pancreatic cancer:3.55e-4 (unfavourable)",Expressed in all,Group enriched,6,epididymis: 581.9;esophagus: 989.7,tonsil: 122.7,Cell line enhanced,,ASC TERT1: 277.2;BJ hTERT+: 233.5;fHDF/TERT166: 213.1;hTEC/SVTERT24-B: 192.3
58,GPR137C,"DKFZp762F0713, TM7SF1L2",ENSG00000180998,G protein-coupled receptor 137C,14,52553148-52637713,Predicted membrane proteins,Evidence at transcript level,"HPA003640, HPA030763",Uncertain,,Approved,Vesicles,,Mixed,Group enriched,6,cerebral cortex: 18.0;epididymis: 10.8;testis: 6.8,gallbladder: 2.1,Mixed,,
59,IGFN1,"DKFZp434B1231, EEF1A2BP1",ENSG00000163395,Immunoglobulin-like and fibronectin type III domain containing 1,1,201190825-201228952,Predicted intracellular proteins,Evidence at protein level,HPA050415,Enhanced,,Approved,Midbody ring,Renal cancer:1.27e-8 (unfavourable),Group enriched,Group enriched,6,endometrium: 17.1;epididymis: 18.4;skeletal muscle: 60.1,cerebral cortex: 5.6,Cell line enriched,6.0,HeLa: 41.8
60,LRRC63,RP11-139H14.4,ENSG00000173988,Leucine rich repeat containing 63,13,46211943-46277366,Predicted intracellular proteins,Evidence at transcript level,"HPA039318, HPA039763",Uncertain,,Approved,Golgi apparatus,,Not detected,Group enriched,6,cerebral cortex: 1.1;epididymis: 1.7;testis: 2.4,fallopian tube: 0.3,Cell line enhanced,,HDLM-2: 1.1
61,NXF2B,bA353J17.1,ENSG00000269437,Nuclear RNA export factor 2B,X,102360395-102463274,Predicted intracellular proteins,Evidence at protein level,HPA002079,Uncertain,,,,,Not detected,Group enriched,6,epididymis: 19.1;testis: 4.9,fallopian tube: 2.1,Cell line enriched,30.0,U-266/84: 25.0
62,PAGE4,"CT16.7, GAGEC1, PAGE-4",ENSG00000101951,PAGE family member 4,X,49829260-49833973,"Cancer-related genes, Predicted intracellular proteins",Evidence at protein level,HPA023880,Enhanced,,Approved,Golgi apparatus<br>Vesicles,,Group enriched,Group enriched,6,epididymis: 1456.6;placenta: 2041.1,prostate: 269.4,Group enriched,9.0,CACO-2: 8.5;U-266/70: 9.3;U-266/84: 33.4
63,PPM1J,"DKFZp434P1514, FLJ35951, MGC19531, PP2Czeta, PPP2CZ",ENSG00000155367,"Protein phosphatase, Mg2+/Mn2+ dependent 1J",1,112709994-112715477,"Enzymes, Predicted intracellular proteins",Evidence at protein level,HPA046045,Uncertain,,Approved,Vesicles,,Mixed,Group enriched,6,epididymis: 22.8;skeletal muscle: 24.1;skin: 21.4;testis: 46.5,heart muscle: 4.7,Cell line enhanced,,T-47d: 18.2
64,PRSS42,TESSP2,ENSG00000178055,"Protease, serine 42",3,46829542-46834095,"Enzymes, Predicted secreted proteins",Evidence at transcript level,HPA046925,Uncertain,,,,,Not detected,Group enriched,6,epididymis: 4.8;heart muscle: 8.8;parathyroid gland: 3.1;skeletal muscle: 8.4;testis: 2.0;thyroid gland: 1.9,"breast,cervix, uterine,prostate,seminal vesicle: 0.7",Cell line enhanced,,NTERA-2: 1.0
65,SCGB1D4,IIS,ENSG00000197745,Secretoglobin family 1D member 4,11,62296277-62299064,Predicted secreted proteins,Evidence at protein level,,,,,,,Tissue enriched,Group enriched,6,"cervix, uterine: 76.0;epididymis: 55.4;fallopian tube: 74.8",endometrium: 11.8,Not detected,,
66,SCGB2A1,"LPHC, MGB2, MGC71973, UGB3",ENSG00000124939,Secretoglobin family 2A member 1,11,62208668-62213939,"Cancer-related genes, Predicted secreted proteins",Evidence at protein level,HPA034584,Enhanced,,,,"Endometrial cancer:1.54e-8 (favourable), Colorectal cancer:1.22e-4 (favourable), Renal cancer:6.36e-4 (favourable)",Group enriched,Group enriched,6,"cervix, uterine: 2863.6;epididymis: 1665.3",fallopian tube: 381.7,Cell line enhanced,,EFO-21: 8.1;NB-4: 1.3;SCLC-21H: 1.9
67,SLC46A2,"Ly110, TSCOT",ENSG00000119457,Solute carrier family 46 member 2,9,112878920-112890913,"Predicted membrane proteins, Transporters",Evidence at transcript level,HPA020098,Approved,,,,,Tissue enhanced,Group enriched,6,"cervix, uterine: 23.3;endometrium: 5.5;epididymis: 5.7;lung: 15.1;skin: 11.3",seminal vesicle: 2.1,Not detected,,
68,STAC2,24b2,ENSG00000141750,SH3 and cysteine rich domain 2,17,39210536-39225872,Predicted intracellular proteins,Evidence at protein level,HPA017288,,,Approved,Nucleoplasm<br>Vesicles,"Endometrial cancer:4.05e-5 (unfavourable), Glioma:5.04e-4 (unfavourable), Ovarian cancer:6.66e-4 (unfavourable)",Group enriched,Group enriched,6,breast: 32.0;cerebral cortex: 30.1;epididymis: 13.8;seminal vesicle: 35.6,skin: 4.5,Cell line enhanced,,HeLa: 22.2;hTEC/SVTERT24-B: 4.8;U-87 MG: 14.4
69,WNK3,PRKWNK3,ENSG00000196632,WNK lysine deficient protein kinase 3,X,54192823-54358642,"Enzymes, Predicted intracellular proteins",Evidence at protein level,HPA077678,,,Approved,Vesicles,,Mixed,Group enriched,6,epididymis: 14.3;testis: 18.6,ovary: 2.6,Cell line enhanced,,AF22: 4.4;HAP1: 5.4;NTERA-2: 9.1;SiHa: 4.8;U-2 OS: 4.1
70,AGRP,"Agrt, ART, ASIP2",ENSG00000159723,Agouti related neuropeptide,16,67482571-67483813,"Disease related genes, Plasma proteins, Predicted secreted proteins",Evidence at protein level,HPA041017,Uncertain,Supported,,,,Mixed,Group enriched,5,adrenal gland: 5.8;epididymis: 24.7,lung: 3.0,Not detected,,
71,ASIP,"AGTIL, ASP",ENSG00000101440,Agouti signaling protein,20,34194569-34269344,Predicted secreted proteins,Evidence at protein level,HPA048636,Uncertain,,Supported,Vesicles,,Mixed,Group enriched,5,epididymis: 18.1;ovary: 7.4;skin: 5.7,breast: 2.0,Cell line enhanced,,CACO-2: 2.6
72,EMX2,,ENSG00000170370,Empty spiracles homeobox 2,10,117542444-117549546,"Disease related genes, Predicted intracellular proteins, Transcription factors",Evidence at protein level,"HPA003497, HPA065294",Enhanced,Supported,Approved,Nucleus,"Renal cancer:2.28e-13 (favourable), Cervical cancer:2.80e-4 (favourable)",Group enriched,Group enriched,5,"cervix, uterine: 59.5;endometrium: 114.9;epididymis: 115.2;fallopian tube: 73.0;kidney: 38.4;seminal vesicle: 65.3;smooth muscle: 59.8",cerebral cortex: 14.0,Cell line enhanced,,EFO-21: 22.1;fHDF/TERT166: 20.9;RPTEC TERT1: 19.9
73,FAM178B,LOC51252,ENSG00000168754,Family with sequence similarity 178 member B,2,96875882-96986592,Predicted intracellular proteins,Evidence at transcript level,"HPA042516, HPA062110",Uncertain,,Uncertain,Nuclear speckles<br>Golgi apparatus,,Tissue enriched,Group enriched,5,bone marrow: 11.4;epididymis: 6.7;spleen: 16.7;testis: 7.4,fallopian tube: 2.0,Cell line enhanced,,K-562: 23.0;RPMI-8226: 19.2;WM-115: 26.6
74,GAMT,"PIG2, TP53I2",ENSG00000130005,Guanidinoacetate N-methyltransferase,19,1397026-1401570,"Disease related genes, Enzymes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins",Evidence at protein level,HPA051806,Approved,,,,Stomach cancer:6.57e-4 (unfavourable),Tissue enriched,Group enriched,5,epididymis: 173.0;liver: 158.9;skeletal muscle: 425.6,pancreas: 48.1,Mixed,,
75,GDF9,,ENSG00000164404,Growth differentiation factor 9,5,132861181-132866884,"Disease related genes, Predicted intracellular proteins, Predicted secreted proteins",Evidence at protein level,HPA069146,Supported,,,,,Tissue enriched,Group enriched,5,epididymis: 5.0;testis: 14.1,thyroid gland: 1.8,Mixed,,
76,HIST1H3A,"H3/A, H3FA",ENSG00000275714,Histone cluster 1 H3 family member a,6,26020490-26020900,Predicted intracellular proteins,Evidence at protein level,HPA042570,Supported,,,,,Mixed,Group enriched,5,bone marrow: 6.7;epididymis: 1.8;testis: 3.7,lung: 0.7,Cell line enhanced,,U-2 OS: 5.3
77,KIAA1210,,ENSG00000250423,KIAA1210,X,119078635-119150579,Predicted intracellular proteins,Evidence at protein level,"HPA000551, HPA048322",Enhanced,,,,,Tissue enhanced,Group enriched,5,epididymis: 47.9;seminal vesicle: 27.4;testis: 58.3,fallopian tube: 8.6,Not detected,,
78,MGAT4C,HGNT-IV-H,ENSG00000182050,MGAT4 family member C,12,85955666-86838904,"Enzymes, Predicted membrane proteins",Evidence at transcript level,HPA016418,Approved,,,,,Tissue enriched,Group enriched,5,cerebral cortex: 5.9;epididymis: 6.7;testis: 5.5;thyroid gland: 15.9,adrenal gland: 1.6,Group enriched,13.0,NTERA-2: 8.7;SCLC-21H: 4.4
79,MYO3B,,ENSG00000071909,Myosin IIIB,2,170178145-170655171,"Enzymes, Predicted intracellular proteins",Evidence at protein level,HPA045483,Approved,,,,,Mixed,Group enriched,5,epididymis: 11.8;kidney: 4.8;parathyroid gland: 15.3;urinary bladder: 4.2,thyroid gland: 1.6,Group enriched,11.0,HDLM-2: 8.9;HEL: 7.8;RT4: 7.8
80,NKAIN1,"FAM77C, FLJ12650",ENSG00000084628,Sodium/potassium transporting ATPase interacting 1,1,31179745-31239554,"Predicted membrane proteins, Transporters",Evidence at transcript level,HPA006873,Uncertain,,,,,Group enriched,Group enriched,5,adrenal gland: 13.9;cerebral cortex: 13.1;epididymis: 4.4;skeletal muscle: 7.4,prostate: 1.9,Cell line enhanced,,AF22: 23.5;AN3-CA: 36.7;NTERA-2: 101.7;SCLC-21H: 35.5;SH-SY5Y: 50.9
81,PAX2,,ENSG00000075891,Paired box 2,10,100735603-100829941,"Disease related genes, Predicted intracellular proteins, Predicted secreted proteins, Transcription factors",Evidence at protein level,"CAB013024, HPA047704, HPA070751",Enhanced,,Supported,Nucleoli<br>Golgi apparatus,Endometrial cancer:4.56e-4 (unfavourable),Group enriched,Group enriched,5,epididymis: 37.1;fallopian tube: 19.0;kidney: 25.3;seminal vesicle: 20.0,"cervix, uterine: 4.9",Group enriched,8.0,AN3-CA: 16.6;EFO-21: 23.1;RPTEC TERT1: 13.3
82,PKHD1,"ARPKD, FCYT, TIGM1",ENSG00000170927,Polycystic kidney and hepatic disease 1 (autosomal recessive),6,51615300-52087625,"Disease related genes, Plasma proteins, Predicted membrane proteins, Predicted secreted proteins",Evidence at protein level,HPA031227,Approved,,,,Renal cancer:9.74e-8 (favourable),Group enriched,Group enriched,5,epididymis: 5.7;kidney: 15.3,pancreas: 1.9,Cell line enriched,7.0,RPTEC TERT1: 8.1
83,PLA1A,ps-PLA1,ENSG00000144837,Phospholipase A1 member A,3,119597842-119629811,"Predicted intracellular proteins, Predicted secreted proteins, RAS pathway related proteins",Evidence at protein level,HPA059740,,,Approved,Nuclear speckles,Cervical cancer:2.81e-7 (favourable),Group enriched,Group enriched,5,epididymis: 164.9;parathyroid gland: 38.9;seminal vesicle: 93.1,liver: 19.6,Cell line enriched,15.0,SK-MEL-30: 19.7
84,SLC27A2,"ACSVL1, FACVL1, FATP2, hFACVL1, HsT17226, VLACS, VLCS",ENSG00000140284,Solute carrier family 27 member 2,15,50182196-50236395,"Enzymes, Predicted membrane proteins, Transporters",Evidence at protein level,HPA026089,Enhanced,,,,"Renal cancer:7.48e-6 (favourable), Urothelial cancer:6.40e-4 (favourable)",Tissue enhanced,Group enriched,5,epididymis: 80.1;kidney: 162.3;liver: 145.5,placenta: 24.7,Cell line enhanced,,HaCaT: 78.4;HL-60: 52.3;SCLC-21H: 47.4
85,SPACA9,"C9orf9, Mast",ENSG00000165698,Sperm acrosome associated 9,9,132878027-132890201,Predicted intracellular proteins,Evidence at protein level,"HPA022243, HPA051600",Enhanced,,Approved,Mitochondria,"Renal cancer:8.31e-4 (favourable), Endometrial cancer:8.61e-4 (favourable)",Expressed in all,Group enriched,5,epididymis: 90.3;fallopian tube: 63.1;testis: 130.1,thyroid gland: 18.0,Mixed,,
86,TAS1R3,T1R3,ENSG00000169962,Taste 1 receptor member 3,1,1331314-1335306,"G-protein coupled receptors, Predicted membrane proteins",Evidence at protein level,HPA053439,Uncertain,,,,,Mixed,Group enriched,5,epididymis: 14.9;salivary gland: 3.3,appendix: 1.7,Cell line enhanced,,Karpas-707: 1.8
87,TRPM5,"LTRPC5, MTR1",ENSG00000070985,Transient receptor potential cation channel subfamily M member 5,11,2404515-2423045,"Predicted membrane proteins, Transporters, Voltage-gated ion channels",Evidence at protein level,"HPA042115, HPA043315",Uncertain,,,,,Tissue enhanced,Group enriched,5,colon: 1.0;duodenum: 2.9;epididymis: 2.2;seminal vesicle: 2.5;small intestine: 2.9,"testis,thyroid gland: 0.4",Not detected,,
